A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Active, not recruiting · Phase 2 · NCT07215312
Conditions: Diabetes Mellitus, Type 2
At a glance
- Research payments reported, 2025
- $137,931
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3938577 (drug), Degludec (drug)
- Dates
- Started 2025-10-13; completion 2026-12
- Results posted
- Not yet
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
From ClinicalTrials.gov, last updated 2026-07-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $137,931 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Girish J. Karamchandani, DO Internal Medicine · Tucson, AZ
- Sandro Bacchelli, MD Family Medicine · Hollywood, FL
- Sureka Bollepalli, M.D. Pediatric Endocrinology · Tampa, FL
- Michael Paul Gimness, M.D. Family Medicine · Plant City, FL
- Rodolfo A. Perez, M.D. Specialist · Hialeah, FL
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Encore Medical Research, LLC $68,708
- Encore Medical Research of Weston LLC $35,708
- Tampa Bay Medical Research Inc $17,891
- Clincial Research of Central Florida $7,419
- Consano Clinical Research LLC $4,792
- Tucson Clinical Research Institute $3,413
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.